Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data
- PMID: 32376044
- DOI: 10.1016/j.ygyno.2020.04.684
Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data
Abstract
Objective: This study aims to investigate the survival impact of minimally invasive surgery on endometrial cancer (EC) patients with different histology and microsatellite status.
Methods: This is a retrospective study based on the Cancer Genome Atlas (TCGA) data. 519 eligible EC patients were divided into four subgroups according to histology and microsatellite status. Kaplan-Meier survival analyses were conducted in all patients and four subgroups to compare the survival outcome after two surgeries (open vs. minimally invasive). Propensity score matching and propensity score covariate adjustment models were used to control confounders. To establish survival prediction models for EC patients, multivariate stepwise Cox regressions were conducted.
Results: Among the eligible patients, 318 (61.3%) received open surgery and 201 (38.7%) received minimally invasive surgery. Overall survival was similar between the two groups (p = 0.33), but the latter showed significantly shorter recurrence-free survival (RFS) (p = 0.005). Subgroup analyses revealed the survival influence of surgical approach was only significant in microsatellite-stable (MSS) endometrioid EC patients. These results were verified by Kaplan-Meier survival analyses after propensity score matching and propensity score covariate adjustment models. Finally, the survival influence of multiple clinicopathological factors was analyzed. After stepwise Cox regressions, minimally invasive surgery was found to be independent risk factor for shorter RFS of all patients (hazard ratio [HR] = 2.038, 95% confidence interval [CI] 1.111-3.741, p = 0.02) and MSS patients (HR = 2.449, 95% CI 1.064-5.639, p = 0.04).
Conclusions: Minimally invasive surgery is associated with more rapid recurrence in MSS endometrioid EC patients, thus indicating the necessity of microsatellite testing for guiding EC surgery.
Keywords: Endometrial neoplasms; Microsatellite repeats; Minimally invasive surgical procedures; Recurrence; Survival.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors have no conflict of interest to disclose.
Similar articles
-
Minimally Invasive Compared With Open Hysterectomy in High-Risk Endometrial Cancer.Obstet Gynecol. 2021 Dec 1;138(6):828-837. doi: 10.1097/AOG.0000000000004606. Obstet Gynecol. 2021. PMID: 34735382
-
Prognostic factors and survival of endometrial cancer: An 11-year retrospective cohort study in southern Taiwan.Taiwan J Obstet Gynecol. 2024 Sep;63(5):679-684. doi: 10.1016/j.tjog.2024.03.019. Taiwan J Obstet Gynecol. 2024. PMID: 39266148
-
Impact of uterine manipulator on oncological outcome in endometrial cancer surgery.Am J Obstet Gynecol. 2021 Jan;224(1):65.e1-65.e11. doi: 10.1016/j.ajog.2020.07.025. Epub 2020 Jul 18. Am J Obstet Gynecol. 2021. PMID: 32693096
-
Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.Gynecol Oncol. 2022 Aug;166(2):236-244. doi: 10.1016/j.ygyno.2022.06.004. Epub 2022 Jun 17. Gynecol Oncol. 2022. PMID: 35725657
-
Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: A systematic review.Eur J Surg Oncol. 2020 May;46(5):782-788. doi: 10.1016/j.ejso.2019.11.519. Epub 2019 Dec 2. Eur J Surg Oncol. 2020. PMID: 31818527
Cited by
-
Open Surgery including Lymphadenectomy without Adjuvant Therapy for Uterine-Confined Intermediate- and High-Risk Endometrioid Endometrial Carcinoma.Curr Oncol. 2022 May 19;29(5):3728-3737. doi: 10.3390/curroncol29050298. Curr Oncol. 2022. PMID: 35621688 Free PMC article.
-
Tumor Molecular Features Predict Endometrial Cancer Patients' Survival After Open or Minimally Invasive Surgeries.Front Oncol. 2021 Feb 26;11:634857. doi: 10.3389/fonc.2021.634857. eCollection 2021. Front Oncol. 2021. PMID: 33718224 Free PMC article.
-
Therapeutic Benefit of Systematic Lymphadenectomy in Node-Negative Uterine-Confined Endometrioid Endometrial Carcinoma: Omission of Adjuvant Therapy.Cancers (Basel). 2022 Sep 17;14(18):4516. doi: 10.3390/cancers14184516. Cancers (Basel). 2022. PMID: 36139675 Free PMC article. Review.
-
FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway.RNA Biol. 2021 Sep;18(9):1265-1278. doi: 10.1080/15476286.2020.1841458. Epub 2020 Nov 5. RNA Biol. 2021. PMID: 33103587 Free PMC article.
-
Identification and validation of hub genes in uterine corpus endometrioid carcinoma: An observational study from TCGA and GEO.Medicine (Baltimore). 2025 May 2;104(18):e42338. doi: 10.1097/MD.0000000000042338. Medicine (Baltimore). 2025. PMID: 40324248 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources